Treatment of endometriosis with a VEGF-targeted conditionally replicative adenovirus

Fertility and Sterility

Volumn 93, Issue 8, 2010, Pages 2687-2694

  Rein, Daniel T ^a   Schmidt, Torsten ^b   Bauerschmitz, Gerd ^a   Hampl, Monika ^a   Beyer, Ines M ^a   Paupoo, Arasen A V ^c   Curiel, David T ^c   Breidenbach, Martina ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Endometriosis; gene therapy; replicating adenovirus; targeting

Indexed keywords

VASCULOTROPIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM CELL; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER; MOUSE; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; UTERUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; FEMALE; GENE THERAPY; HUMANS; MICE; MICE, INBRED C57BL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952321586     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.04.042     Document Type: Article

References (26)

1. Giudice L.C., and Kao L.C. Endometriosis. Lancet 364 (2004) 1789-1799
2. Ramon L., Gilabert-Estelles J., Castello R., Gilabert J., Espana F., Romeu A., et al. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay. Hum Reprod 20 (2005) 272-278
3. Dlugi A.M., Miller J.D., Knittle J., and Lupron Study Group. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril 54 (1990) 419-427
4. Whitehouse R.W., Adams J.E., Bancroft K., Vaughan-Williams C.A., and Elstein M. The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clin Endocrinol (Oxf) 33 (1990) 365-373
5. Hughes E., Fedorkow D., Collins J., and Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev (2003) CD000155
6. Rein D.T., Breidenbach M., and Curiel D.T. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2 (2006) 137-143
7. Raki M., Rein D.T., Kanerva A., and Hemminki A. Gene transfer approaches for gynecological diseases. Mol Ther 14 (2006) 154-163
8. Huard J., Lochmuller H., Acsadi G., Jani A., Massie B., and Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 2 (1995) 107-115
9. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 6 (2000) 45-55
10. Donnez J., Smoes P., Gillerot S., Casanas-Roux F., and Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 13 (1998) 1686-1690
11. Takehara M., Ueda M., Yamashita Y., Terai Y., Hung Y.C., and Ueki M. Vascular endothelial growth factor A and C gene expression in endometriosis. Hum Pathol 35 (2004) 1369-1375
12. Hull M.L., Charnock-Jones D.S., Chan C.L., Bruner-Tran K.L., Osteen K.G., Tom B.D., et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 88 (2003) 2889-2899
13. Machado D.E., Abrao M.S., Berardo P.T., Takiya C.M., and Nasciutti L.E. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 90 (2008) 148-155
14. Di Carlo C, Bonifacio M, Tommaselli GA, Bifulco G, Guerra G, Nappi C. Metalloproteinases, vascular endothelial growth factor, and angiopoietin 1 and 2 in eutopic and ectopic endometrium. Fertil Steril. Published online July 19, 2009 [Epub ahead of print].
15. Ryan I.P., Schriock E.D., and Taylor R.N. Isolation, characterization, and comparison of human endometrial and endometriosis cells in vitro. J Clin Endocrinol Metab 78 (1994) 642-649
16. Takayama K., Reynolds P.N., Adachi Y., Kaliberova L., Uchino J., Nakanishi Y., et al. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application. Cancer Gene Ther 14 (2007) 105-116
17. Nap A.W., Griffioen A.W., Dunselman G.A., Bouma-Ter Steege J.C., Thijssen V.L., Evers J.L., et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 89 (2004) 1089-1095
18. Park A.C.P., Ferin M., Xiao E., and Zeitoun K. Inhibition of endometriosis development in Rhesus monkeys by blocking VEGF receptor: a novel treatment for endometriosis. Fertil Steril (2004) 82
19. Dabrosin C., Gyorffy S., Margetts P., Ross C., and Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 161 (2002) 909-918
20. Rein D.T., Breidenbach M., Kirby T.O., Han T., Siegal G.P., Bauerschmitz G.J., et al. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 11 (2005) 1327-1335
21. Lieber A., He C.Y., Meuse L., Schowalter D., Kirillova I., Winther B., et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71 (1997) 8798-8807
22. Gyorffy S., Palmer K., and Gauldie J. Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am J Pathol 159 (2001) 1137-1147
23. Gyorffy S., Palmer K., Podor T.J., Hitt M., and Gauldie J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined antiangiogenesis and immunotherapy. J Immunol 166 (2001) 6212-6217
24. Fortin M., Lepine M., Merlen Y., Thibeault I., Rancourt C., Gosselin D., et al. Quantitative assessment of human endometriotic tissue maintenance and regression in a noninvasive mouse model of endometriosis. Mol Ther 9 (2004) 540-547
25. Othman E.E., Salama S., Ismail N., and Al-Hendy A. Toward gene therapy of endometriosis: adenovirus-mediated delivery of dominant negative estrogen receptor genes inhibits cell proliferation, reduces cytokine production, and induces apoptosis of endometriotic cells. Fertil Steril 88 (2007) 462-471
26. Kirn D., Martuza R.L., and Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7 (2001) 781-787